deltatrials

HIV infections Trials in Durban, South Africa

Conditions / HIV infections / Durban, South Africa

HIV infections has been the subject of sustained clinical investigation across multiple research sites.

73 total trials for this combination

Showing top 10 of 73 trials

Trials

NCT ID Title Status Phase
NCT01231516 A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults COMPLETED PHASE3
NCT02362503 Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients ACTIVE_NOT_RECRUITING PHASE3
NCT00540449 TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine. COMPLETED PHASE3
NCT00062660 Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection APPROVED_FOR_MARKETING
NCT02951052 Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults ACTIVE_NOT_RECRUITING PHASE3
NCT05168813 Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern COMPLETED
NCT00050895 Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients COMPLETED PHASE3
NCT03299049 Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults ACTIVE_NOT_RECRUITING PHASE3
NCT02938520 Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants ACTIVE_NOT_RECRUITING PHASE3
NCT05168813 Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern COMPLETED

Related Pages